Skip to main content
. Author manuscript; available in PMC: 2019 Nov 19.
Published in final edited form as: Gynecol Oncol. 2017 Aug 8;149(1):12–21. doi: 10.1016/j.ygyno.2017.07.145

Fig. 4.

Fig. 4.

Molecular alterations that vary by race and age in endometrial cancer. Endometrial cancer patients with clinical data including race and age at diagnosis, and mutation status for TP53 or PTEN (N = 219), or one of the aggressive molecular subtypes including the integrative copy number (CNV) high subtype (N = 204), transcript-based mitotic subtype (N = 300), and somatic copy number alteration (SCNA)-based cluster 4 subtype (N = 327) from the Cancer Genome Atlas Research Network were evaluable for analysis. Fisher’s exact test was used to compare proportions between groups. The bar chart displays the proportion of white patients diagnosed at < 65 years of age, white patients diagnosed at 65+ years of age, black patients diagnosed at < 65 years of age, or black patients diagnosed at 65+ years of age with a TP53 mutation, wild-type PTEN, CNV High subtype, Mitotic subtype or Cluster 4 subtype. Mutations in TP53, wild-type PTEN and the three aggressive molecular subtypes were significantly more common in black vs. white endometrial cancer patients and in patients diagnosed at 65+ vs. <65 years of age.